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ABSTRACT 
 
Cutis laxa (CL) is a disorder with multiple etiologies characterized by defective or 
deficient production of elastin. Previous research has suggested that a significant portion of cases 
of CL are due to some type of mitochondrial dysfunction. Recent clinical cases implicate 
mitochondrial ribosomal protein S2 (MRPS2) as a possible cause of autosomal recessive CL. 
Despite this, in vitro tissue culture knockout of MRPS2 has not been seriously investigated as a 
model for studying the pathology of mitoribosomal mutation-caused wrinkly skin at a cellular 
and tissue level. In this study, we used CRISPR/Cas9 to lower the activity of MRPS2 in rat lung 
fibroblasts. We generated one heterozygous mutant with a mutation in one allele of exon 4, and 
two biallelic mutants, each with unique mutations in both alleles of exon 3. The biallelic 
mutations resulted in aberrant mRNA products, including skipping of exon 3 in both biallelic 
mutants and insertion/deletion mutations unique to each mutant. Analysis of secreted protein and 
lysate by immunoblotting revealed two MRPS2 fragments, around 8 and 33 kilodaltons in mass, 
respectively. Immunostaining of biallelic mutant cell lines revealed altered organization and 
reduced abundance of elastic fibers along with alterations in nuclear and cellular morphology 
and cell growth rates.  
Zsolt Urban, PhD 
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Public Health Significance: The study of the importance of mitoribosomal assembly for 
fibroblast health has consequences for both the study of cutis laxa and the more general study of 
the molecular pathogenesis of skin wrinkling.  
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1.0  BACKGROUND 
1.1 THE EXTRACELLULAR MATRIX 
The extracellular matrix (ECM) is the superstructure of molecules that connect and 
support cells in a multicellular organism. Far from being an inert, homogenous scaffold 
envisioned by early biologists, the ECM is a dynamic and complex system of proteoglycans, 
polysaccharides, and proteinaceous fibers that support the healthy development of individual 
cells. The ECM supports the proliferation of fibroblasts by clearing harmful reactive oxygen 
species, mediating pH, hydration, ionic concentration, and supplying optimal levels of growth 
factors and other hormones. (Freedman et al., 2015) (Chuang et al., 2014)In addition to 
providing structural support and a scaffold for cells, networks of extracellular proteins signal 
cells to grow, divide, enter senescence, or undergo apoptosis by providing signals via 
transmembrane proteins. A complex network of fibers, mainly elastin and fibrillin, interact at the 
molecular and fibrillar levels to give the elastic tissues their unique biomechanical properties. 
(Chuang et al., 2014)In addition to being an important component of skin, elastic fibers play a 
critical role in the proper function of large arteries and lungs. (Baldwin et al., 2013) 
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1.2 ELASTIN 
Elastin is a polymer with a complex supramolecular structure, and is composed of 
monomers of the polypeptide tropoelastin. In mammals, there is only one tropoelastin gene, 
ELN, which contains 34 exons. (Rosenbloom et al., 1995)These exons are expressed as various 
isoforms, and 13 specific isoforms have been identified in the lungs, the skin, the heart, the large 
arteries, the cartilage and the muscles (http://www.uniprot.org/uniprot/P15502). Due to the large 
size of the elastin polymers, elastin assembly occurs largely in the extracellular space. As 
effective exocytosis of large quantities of tropoelastin is necessary for proper elastic fiber 
biosynthesis, vesicular transport is one stage of the elastin biosynthesis pathway that is often 
found to be disrupted in wrinkly skin disease (Urban and Davis, 2014).  
1.3 FIBRILLIN 
In addition to elastin, the fibrillins are the second major component of elastic fibers 
(Davis and Summers, 2012). Humans have three elastin genes (FBN1, FBN2, FBN3). The FBN1 
gene is the predominant form of fibrillin, a 350 kilodalton glycoprotein(Sakai et al., 1986). 
Fibrillin monomers assemble into 10-12 nm microfibril, which provide a scaffold for the 
deposition of tropoelastin (Jensen et al., 2012)In addition to their structural role, the microfibrils 
contain essential binding domains for growth factors, the disruption of which can result in 
signaling changes that contribute to diseases such as Marfan syndrome (Bolar et al., 2012).  
 3 
1.4 CUTIS LAXA 
Cutis laxa is a disease with multiple etiologies characterized by deficiency in the 
production of healthy elastic fibers (Berk et al., 2012). Symptoms can range from simple 
superficial laxity of skin to fatal cardiovascular and pulmonary dysfunction. The majority of 
cases of cutis laxa are thought to be hereditary, but in only about 40% of cases is a single gene 
implicated. Of the cases with a certain genetic cause, roughly 10% of cases involve a mutation in 
the ELN gene itself. Other, less common subtypes reflect the cellular pathways involved in the 
secretion of elastic fibers and maintenance of the extracellular matrix. Mutations in the ATPase 6 
gene, an ATP-powered proton pump responsible for maintaining pH in secretory vesicles, is one 
significant cause of cutis laxa. Another gene that has been implicated is the ATPase 7, which is 
responsible for maintaining Cu2+ ion transport. Mutations in the latent transforming growth 
factor beta binding protein 4 (LTBP4) gene, have also been identified as a cause in several cases 
of cutis laxa (Urban and Davis, 2014).  
1.5 MITOCHONDRIAL DISEASE 
Mitochondrial disorders are genetically and phenotypically heterogeneous, with severity 
ranging from subclinical deficits in energy to death at the embryonic stage. About 15% of 
diagnosed cases of mitochondrial disease can be attributed to mutations in the mitochondrial 
genome itself, which codes for mitochondrial tRNAs, certain core electron transport chain (ETC) 
proteins, while the rest are caused by mutations in nuclear genes coding for the other ~1500 
proteins present in the mitochondrion(Hatakeyama and Goto, 2016). Variation in manifestations 
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is considerable, even between people with the same mutation, and lesions generally affect tissues 
and organs with higher energy requirements such as the liver, the muscles, and the nervous 
system, especially the brain, ears, and eyes. Diagnosed mitochondrial diseases have a prevalence 
of about 1:5000, but as they are often not recognized by physicians, the actual number could be 
higher (Liang et al., 2014).  
1.6 MITOCHONDRIAL RIBOSOMES 
Human mitochondrial ribosomes are distinct from their cytoplasmic counterparts in many 
ways. Human mitochondrial ribosomes are less massive than human cytoplasmic ribosomes; 
they are about the same molecular mass as prokaryotic ribosomes but most of the mass in human 
mitochondrial ribosomes is protein subunits compared to prokaryotic ribosomes where a greater 
proportion of the ribosome is composed of rRNA(De Silva et al., 2015). A significant portion of 
the extra protein serves the function of replacing rRNA, which makes up a smaller proportion of 
the mitoribosome when compared to both the mammalian cytoplasmic ribosome and the E. coli 
ribosome (Koc et al., 2001).The mitochondrial ribosomal protein genes are located in the 
nucleus, and the proteins contain a localization signal that is cleaved upon import into the 
mitochondrion (Luciano and Geli, 1996) (Oshima et al., 2005). In the ophistokonts (a 
phylogenetic group which includes metazoans and fungi) the mitoribosome is permanently 
tethered to the mitochondrial membrane, while in plants it floats freely in the intermembrane 
space. The mitochondrial ribosomes are responsible for translating mRNAs that code for 13 
proteins in the electron transport chain The mitochondrial genome also contains genes for 22 
tRNAs and 2 ribosomal RNAs (Shokolenko and Alexeyev, 2015). Because the electron transport 
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chain is responsible for oxidative phosphorylation of ATP, defects in mitochondrial ribosome 
proteins can impair production of electron transport chain proteins, leading to defective 
OXPHOS. The effects of defects in mitochondrial protein synthesis can range from embryonic 
lethality to slightly lowered energy, and can affect every organ system (Shokolenko and 
Alexeyev, 2015). Though most mitochondrial diseases involve many organ systems, many MRPs 
have tissue-specific isoforms that are mediated by alternative proteolysis, defects in which can 
lead to disorders of a single tissue or organ system. (Nouws et al., 2016)(Williams et al., 2014)  
1.7 MITOCHONDRIAL RIBOSOMAL PROTEIN S2 
MRPS2’s possible relevance to wrinkly skin disorders became apparent when two 
unrelated families with cutis laxa were found to have biallelic mutations in the gene  (Wevers et 
al., personal communication). Subjects in these two families presented with hypoglycemia, 
sensorineural hearing impairments, and mild developmental delay. Taken together, these 
symptoms suggest some mitochondrial involvement, and exome sequencing of these two 
individuals revealed that both patients had mutations in the gene MRPS2. Previously, mutations 
in MRPS16 and MRPS22 had been linked to wrinkly skin, but not MRPS2. In both cases, the 
patients’ parents were unrelated and the disease appears to have been inherited in an autosomal 
recessive fashion. One patient is a compound heterozygote with a mutation at c.328C>T 
(p.Arg110Cys) and a mutation at c.340G>A(p.Asp114Asn) and the other patient is homozygous 
for sequence variant c.413G>A (p.Arg138His) 
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Not very much is known about MRPS2, specifically, as the bulk of studies on the mitoribosomes 
have focused on the proteins in aggregate. RNAseq studies have found a number of associations 
between various diseases and up- or down- regulation of various mitochondrial ribosomal 
subunit proteins. MRPS2 has been found to be upregulated in bladder and colorectal cancers, and 
downregulated in head and neck cancers (Gopisetty and Thangarajan, 2016). Based on sequence 
information, the MRPS2 gene contains 5 exons, though the coding region only starts late in exon 
2. The MRPS2 gene does not appear to be very heavily conserved compared to cytosolic 
ribosomal protein subunit genes. The homology between murine MRPS2 and human MRPS2 is 
77.13%. By comparison, the homology between murine and human cytosolic ribosomal protein 
subunit 10 is 97% (Genecards).  
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2.0  MATERIALS AND METHODS 
To complete this experiment, we used the chemicals, kits, antibodies and machines listed 
in tables 1, 2, and 3 below. AM9780 
2.1 MATERIALS 
Table 1. Chemicals and Kits 
Product Manufacturer Catalog # 
4X Laemmli Sample Buffer  Bio-Rad #161-0747 
Antibiotic Antimycotic Solution 
(100x), Stabilized Sigma-Aldrich A5995-100ML 
Bio-rad protein assay dye reagent 
concentrate Bio-Rad 5000006 
Bovine Serum Albumin Sigma A2153-50G 
Bromochloropropane Molecular Research Center BP151 
Cell Lytic™M Cell Lysis Reagent Sigma C2978-250ML 
Cytoseal™ 60 Richard-Allan Scientific 8310-16 
Dimethyl Sulfoxide (DMSO) Fisher Biotech BP231-1 
Dulbecco’s Modified Eagle Medium 
[high glucose] Gibco 12100-046 10x1L 
4',6-diamidino-2-phenylindole 
(DAPI) Sigma-Aldrich D9542-1MG 
Disposable Cell Scraper Fisher Scientific 08-100-241 
Ethyl Alcohol, 200 Proof Decon Laboratories, Inc. 04-355-222 
Fetal Bovine Serum Sigma-Aldrich 12303C-500ML 
Glycine Fisher Bioreagents BP381-5 
Geneticin Gibco 10131-027 
Halt™ Protease Inhibitor Cocktail, 
EDTA-free (100X) Thermo Scientific 78437 
HEPES Fisher Bioreagents BP310-500 
Isopropanol     
LB Agar, Miller Fisher Bioreagents BP1425-500 
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Table 1 Continued 
LB Broth, Miller Fisher Bioreagents BP1426-500 
2-Mercaptoethanol Bio-Rad #161-0710 
Methanol Fisher Chemical A454-4 
Mini-PROTEAN® TGX™ Gels, 10-
well comb, 50µl Bio-Rad 456-9034 
Nuclease-Free Water Ambion AM9932 
Odyssey® Blocking Buffer (PBS) Li-Cor 927-40000 
One Shot® TOP10 Chemically 
Competent E. coli Invitrogen C404006 
Phosphate Buffered Saline Lonza 17-516F 
Protease Inhibitor Cocktail Sigma-Aldrich P1860-1ML 
Puromycin 10 mg/ml Gibco A11138-02 
Sodium Bicarbonate Fisher Scientific SS33-3 
RNAse Zap® Ambion AM9780 
TOPO TA Cloning® Kit Dual 
Promoter pCR® II-TOPO® Vector Invitrogen K4600-01 
Tris Base Fisher Bioreagents BP152-5 
Triton®-X-100,  electrophoresis grade Fisher Biotech BP151-500 
TRIzol™ Reagent Invitrogen 15596018 
Trypsin-EDTA Solution Sigma T4049-100ML 
TWEEN 20 Fisher Bioreagents BP337-500 
 
Table 2. Antibodies 
Antibody Company Catalog # 
Alexa fluor 488 donkey Anti-
Rabbit IgG Invitrogen 
A21206 
 
Alexa fluor 594 donkey Anti-
mouse IgG 1/1000 Invitrogen 
A21424 
 
c-myc (A-14)-G antibody 
produced in Goat 
Santa Cruz 
sc-789-G 
 
IRDye 680LT conjugated donkey 
anti-goat IgG 
 
Licor 926-68024 
 
IRDye 800 goat anti-mouse IgG1 Licor 926-3250 
Anti-MRPS2, antibody produced 
in mouse, purified 
immunoglobulin Sigma-Aldrich SAB1407444-50UG 
Mouse Anti-fibrillin Monoclonal 
Antibody raised against human 
fibrillin 1 
Chemicon MAB1919 
 
Rat Lung α-Elastin Goat 
polyclonal antiserum 
Elastin Products Company, Inc. RA75 
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Table 3. Machines 
Machine Manufacturer Catalog # 
Cimarec®2 Hotplate Thermolyne HP88857104 
Cellometer® Mini Nexcelom 1001201 
Centrifuge 5424R Eppendorf 022620461 
Centrifuge 5702 Eppendorf 5702000019 
Digital Dry Bath Labnet International Inc. D1200 
Electrophoresis Power Supply 
EPS 30 
Amersham Pharmica Biotech 18-1130-01 
Excella E24 Incubator/Shaker  New Brunswick Scientific 14-285-732 
GeneAmp® PCR System 9700 Applied Biosystem N8050200 
Isotemp 228 Water Bath Fisher Scientific 15-462-28Q 
NanoDrop 2000c 
Specrophotometer 
Thermo Scientific ND-2000C 
NUAI Laminar Flow Hood   
Olympus CKX41 Centrifuge Olympus Life Science  
PB5001 Scale  Mettler Toledo PB5001-S/A,PB5001-S/M 
Power PAC 3000 Bio-Rad 51907-1 
Sorvall Legend XIE Centrifuge  Thermo Scientific 75004505 
Steri-Cycle CO2 Incubator, 
HEPA Class 18 
Thermo Electron Corporation 201370 
Synergy UV Millipore Corporation CDUFB1001 
UltraBasic UB-10 pH meter Denver Instrument  
VariMix Platform Thermoline M79735 
Vortex Genie Scientific Industries Inc. 12-812 
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2.2 METHODS 
2.2.1 Production and verification of mutant cells 
2.2.1.1 Design of guides and insertion into plasmid vector 
Three sets of CRISPR-associated guides were designed to target exons 2, 3, and 4 of the 
rat MRPS2 gene. These exons were selected for targeting because they form the bulk of the 
MRPS2 transcript and include highly-conserved regions that are likely of biological significance. 
Using a tool designed by Dr. Zhang of MIT, (Ran et al., 2013)we designed the 3 sets of guides to 
maximize the possibility of obtaining mutants. The PX495 plasmid contains constitutively 
expressed genes for both ampicillin and puromycin resistance, which allows for selection against 
bacteria and eukaryotic cells lacking the plasmid respectively. The expression of the guide RNA 
is driven by a U6 promoter, and the plasmid encodes a Cas9 nuclease containing a nuclear 
localization signal (Figure 1). The expression of Cas9 is driven by a cytomegalovirus hybrid 
enhancer/promoter. Guide RNA sequences were designed as pairs of complementary synthetic 
oligonucleotides modified at their 5’-ends with a phosphate group to facilitate ligation into the 
PX495 plasmid digested with the BbsI restriction endonuclease. After ligation, competent Top-
10 E. coli cells were transformed with the recombinant plasmids were transformed, and were 
plated onto LB Agar plates containing 50µg/ml ampicillin and left to grow overnight in an 
incubator at 37°C. The following day, 12 E. coli colonies per construct were picked and placed 
in tubes containing 10mL LB medium with 50µg/ml ampicillin, and left in a shaking incubator to 
grow overnight at 37°C. The following day, plasmid DNA was isolated from these colonies 
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using a mini-prep kit (Qiagen). The extracted plasmid DNA was subjected to agarose gel 
electrophoris to identify the plasmid clones containing the insert. The band corresponding to the 
plasmid with the insert was cut out and purified with a gel purification kit (Qiagen). The insert 
region of the purified plasmid was examined using Sanger sequencing to confirm that the desired 
guides had been successfully cloned into the vector. 
 
Table 4. Guide Sequences 
Guide Sequence # offtarget 
sites (# offtarget sites 
in genes)  
least 
#mismatches 
(#sites w/ least # 
of mismatches) 
E2 Guide 5’ CCGCTCCGGCTGTGCTGACC 3’ 113 (17) 2 (3) 
E3 Guide 5’ GTCCCCGCAGTCAGCGAGCC 3’ 291 (27) 3 (9) 
E4 Guide 5’ TTCGAGGCCCGAGTACACCT 3’ 39 (5) 3 (2) 
 
Table 5. Px459 Sequencing Primer 
Primer Name Description Sequence 
LKO. 1 5’ Px459 CMV fw seq 
primer 
5’ 
CGCAAATGGGCGGTAGGCGTG 
3’ 
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Figure 1. Px459 plasmid vector.  
Legend, clockwise from top: U6 promoter, LKO 1.5 sequencing primer region, BbsI cloning 
sites, Cas 9 nuclease sequence, Puromycin resistance cassette, Ampicillin resistance cassette, 
pUC origin of replication 
2.2.1.2 Transfection, selection, and expansion of RFL6 cells 
A vial of frozen RLF6 cells was thawed and seeded into a 10-cm dish (Falcon) and 
transferred to 2 6-well plates. When the cells reached 80% confluence, plasmids were transfected 
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into 10 of the 12 wells. 3 wells per exon were transfected with plasmids containing the guides 
corresponding to each exon, and an additional well was transfected with an unmodified version 
of the plasmid as a negative control. The 2 remaining wells were used as controls; one well was 
treated with transfection reagents but no plasmid, and the other well was not treated with any 
transfection reagents, nor was any DNA introduced. The cells were exposed to the 
lipofectamine-plasmid complex for 24 hours, at which point the media was aspirated and 
replaced with Dulbeco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum 
(FBS) and 1% antibiotic-antimycotic solution (ABAM). After 24 hours, the regular 10% FBS 
1% ABAM DMEM was replaced with 10%FBS 1%ABAM DMEM containing 1.5 µg/mL 
puromycin to select for cells transfected with the plasmid. At 1 week, the cells were expanded 
from the wells into 10-cm dishes (Falcon). After 2 weeks, the 2 dishes containing un-transfected 
cells contained no live cells. Due to low survival of cells after employing this selection timetable, 
a second round of selection with modified parameters was employed: all the conditions described 
above were identical, except the selection period was shortened to one week and the 
concentration of puromycin in the media was decreased to 1µg/ml. In both cases, surviving cells 
were expanded into progressively larger plates. When these became confluent, the cells were 
expanded into 2 15-cm plates per transfection; one 15-cm plate per transfection was frozen in 
10%DMSO for later use while the other was harvested for DNA using a DNeasy Blood & Tissue 
Kit (QIAGEN).  
2.2.1.3 Clonal isolation of RFL6 mutants 
After confirming mutations in the RFL 6 transfectants, we proceeded to isolate clonal 
populations of RLF6 cells using a technique of serial limiting dilutions using 96-well plates 
(Corning.) Colonies of cells representing the daughters of single cells were identified by 
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microscopy and grown to confluence, at which point they were trypsinized and expanded to 24-
well plates (Corning.) Individual clones were grown and expanded as they reached confluence 
into 3.5-cm dishes, 5-cm dishes, and 10 cm dishes.  Clones were then harvested for DNA 
extraction. Selected clones were seeded onto coverslips and subjected to immunohistostaining to 
visualize elastin and tropoelastin expression in mutants compared to wild-type RLF6 cells.  
2.2.1.4 Analysis of RFL6 cell DNA 
The DNA obtained from the 15-cm plates was amplified using PCR primers 
corresponding to each targeted exon. The amplified exonic DNA was inserted into TOP 10 
competent E. coli and plated onto ampicillin-containing LB Agar plates. Clones were picked and 
amplified in LB media containing ampicillin in a shaking incubator, and the DNA isolated using 
a Maxi Prep kit (QIAGEN).  6 clones per exon were sent for sequencing of the corresponding 
targeted regions.  
2.2.1.5 Design of Myc-tagged MRPS2 construct 
To verify the affinity of the MRPS2 antibody for MRPS2, two c-myc fusion genes were 
produced using the Gibson Assembly® Cloning Kit (New England BioLabs). Two sets of PCR 
primers, one of which flanks the entire MRPS2 transcript and one of which spans from the start 
codon to a premature stop in Exon 2, were used to amplify DNA from the human MRPS2 gene, 
which was then inserted into the pcDNA3.1(+)/myc-His B plasmid (Figure 2). The plasmid was 
transformed into using NEB® 5-alpha competent E. coli, clones were isolated and plasmid DNA 
extracted using a MaxiPrep kit (Qiagen).  The insertion of the cDNA sequences into the plasmid 
was confirmed using Sanger sequencing. (fig) One clone each for wild type and truncated 
MRPS2 transfected into RFL6 cells using Lipofectamine 3000 transfection reagent 
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(ThermoFisher). Transfected cells were subjected to selection with 200 μg/mL geneticin to 
obtain stably transfected cell lines. 
 
Figure 2. The map of the pcDNA myc-His(-)B 3.1 plasmid vector. 
Legend, clockwise from top: T7 promoter, restriction sites, myc polypeptide sequence, 
polyhistidine-tag, termination signal, f1 origin of replication, SV40 origin of replication, 
Neomycin resistance cassette, SV40 poly-A, pUC origin of replication, Ampicillin resistance 
cassette, CMV promoter 
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2.2.2 RNA Analysis 
2.2.2.1 RNA Isolation 
RNA from wildtype, E4 mutant, and E3 mutant cell lines, as well as a cell line that was 
transfected with the PX459 plasmid and cloned but not found to contain any mutations, was 
obtained using the TRIzol® extraction method for RNA isolation. One 15-cm dish per cell line 
was treated with 8mL Trizol® and RNA was isolated using a method similar to that described in 
(Rio et al., 2010) except with 1-bromo-3-chloropropane (BCP) (Chomzynski 1995). The media 
from one 15-cm plate per cell line was aspirated, and replaced with 8mL Trizol. After 5 minutes 
of incubation, the trizol/nucleoprotein complex was mixed vigorously with 1 mL of BCP per 
sample, then incubated for 3 minutes. The tubes were centrifuged at 12,000 g for 12 minutes at 
4°C to separate the protein and DNA phase from the RNA phase. The supernatant containing the 
RNA was transferred to tubes containing 4mL of ice-cold isopropanol per sample, shaken 
vigorously for 24 seconds, and left sitting for 12 minutes before being transferred back to the 
centrifuge and spun again at 12,000g for 12 minutes at 4°C. The supernatant was carefully 
decanted, and the RNA pellet was washed with 70% Ethanol in ddH2O, then centrifuged for 6 
minutes at 4°C. The ethanol was carefully poured out, and the pellet allowed to air-dry for 12 
minutes. The dried RNA pellets were each dissolved in 160μL of nuclease-free water. These 
stock solutions were measured using the Nanodrop 2000 (Thermo Scientific), and used to create 
standardized 100ng/μL solutions of RNA. 
2.2.2.2 Reverse Transcription 
To get an accurate measurement of MRPS2 mRNA levels in the different cell lines 700 
nanograms of RNA was used to create cDNA copies by reverse transcription (Superscript® IV 
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First-Strand cDNA Synthesis Kit from Thermo Fisher). The cDNA was then used to quantify 
MRPS2 mRNA levels using TaqMan® qPCR probes for rat MRPS2 and human GAPDH (rat 
GAPDH can be detected using human GAPDH probes, due to high sequence homology). cDNA 
was pipetted into 16 wells per sample, (8 replicates for GAPDH and 8 replicates for MRPS2) to a 
final dilution of 1/45, to minimize error.   
Primers were designed to flank exons 3 and 4 to determine the relative abundance of the 
various truncated or expanded mRNA transcripts (see table and figure below.) The primers were 
designed such that the PCR products would be small enough for expansions and deletions to be 
readily detectable on a gel. 
Table 6. Primers for amplification of cDNA copies of mRNA 
Location Sequence 
Exon 1 5’ CTCACACGCATGGCCAAA 3’ 
Exon 2 5’ CATCTCAGTCCACGCGCCTA 3’ 
Exon 4 5’ GCAACCGGCTTTATGTCCCA 3’ 
Exon 5 5’ GGCGGTTCCCAAAGATGTAT 3’ 
 
 
Figure 3. Relative positions of PCR primers on the MRPS2 cDNA. 
Arrows indicate extent of primer regions and primer direction. Arrow length and exon length are 
to scale. 
 
Complementary DNA from WT, E4 mutant, and both biallelic E3 mutant cells was 
amplified using the following primer combinations: E1 and E4, E2 and E4, E2 and E5, E1 and 
E5. After it was found that any combination involving E1 failed to yield any PCR product, the 
E2/E4 and E2/E5 amplifications were repeated and a gel image was captured. Based on the 
image, it was decided that the E2/E5 PCR products for the E4 mutant cDNA and both biallelic 
E3 mutant cDNAs would be good candidates for sequencing. The PCR products were cloned 
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into competent E. coli using the TOPO-TA Cloning Kit from Invitrogen and 14 clones per PCR 
product were expanded and the DNA was extracted using Monarch Mini-Prep kits and sent for 
sequencing. 
2.2.2.3 Statistical Analysis 
qPCR data is presented as mean ± SD. All statistical analyses were preformed using R 
statistical software, v. qPCR assays were performed in octuplicate, and the mean was used for 
statistical analysis. Statistical significance was set at p <.05.  
2.2.3 Protein Analysis 
2.2.3.1 Protein extraction 
Secreted proteins were collected by washing 15cm plates of confluent cells with warm 
PBS 3 times, then incubating the plates with 15ml of serum-free DMEM per plate overnight. The 
media was then centrifuged for 12 minutes at 4000rpm at 4°C to remove debris and dead cells, 
and the supernatant was transferred to a concentrating filter with 3 kilodalton pores (Amicon). 
The media was centrifuged at 4000rpm at 4°C to concentrate it to a final volume of <500μL. 
Cellular proteins were collected by lysis and homogenization. Confluent 15cm plates 
were washed 3 times with cold PBS, then treated with 1175μL Cell Lytic M lysis buffer 
supplemented with 10 μl protease inhibitor and 10 μl phosphatase inhibitor. The cells were put 
on a shaker with light shaking for 5 minutes at 4°C, and scraped with a cold cell scraper. The 
resulting lysate was transferred to a cooled glass homogenizer and liquefied with 24 strokes. 
Then, the lysate was transferred to a 1.5ml reaction tube and centrifuged at 13000 rpm at 4°C for 
20 minutes. 
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2.2.3.2 Protein concentration verification 
Both secreted proteins and cellular proteins were quantified using standard curves. 
Bovine serum albumin was diluted to final concentrations of 2μg/mL, 4μg/mL, 6μg/mL, 
8μg/mL, and 10μg/mL, and mixed with either lysis buffer or serum-free DMEM to a final 
concentration of 1μl/mL, an mixed with water and 200μL Bradford’s reagent to a final volume of 
1ml. The protein samples were mixed with water and 200μL Bradford’s reagent to a final 
concentration of 1μL/mL and a final volume of 1mL. The samples were incubated in the dark at 
room temperature for 30 minutes and the absorbances were measured with a Nanodrop 2000 
spectrophotometer (Thermo Scientific.) The resulting curves were used to determine 
concentrations of the protein samples.  
2.2.3.3 SDS-PAGE Electrophoresis  
Mercaptoethanol and 4x Laemmli Buffer were mixed in a 1:9 ratio, to create a denaturing 
loading buffer, which was then mixed with the protein samples and incubated at 95°C on a 
heating block for 5 minutes. The samples were then pipetted into wells of a 4-20% Mini-Protean 
TGX precast gel (Biorad), with total protein standardized to 60μg per well for the lysate protein 
samples, and 80μg per well for the secreted protein samples. The gel was placed in a cell filled 
with ice-cold running buffer (9g tris base, 43.2g glycine, 1200mL water, 15mL 10% SDS) and 
connected to a power-pack. The cell was placed in an ice bucket and the gel was subjected to 
constant voltage of 100V for 75 minutes. 
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2.2.3.4 Membrane transfer 
After 75 minutes, the gel was removed from the housing and carefully transferred to 
blotting buffer (2.4g Tris, 11.5g Glycine, 800ml H2O, 200ml Methanol) where it was allowed to 
equilibrate for 15 minutes. Towards the end of this incubation, a piece of polyvinylidene fluoride 
(PVDF) membrane for each gel was activated in methanol for 15 seconds then allowed to 
equilibrate in blotting buffer for 5 minutes. A transfer assembly was then constructed in the 
following order: Cathode, sponge, 4 pieces of filter paper, gel, PVDF membrane, 4 pieces of 
filter paper, sponge, and anode. The assembly was submerged in ice-cold blotting buffer along 
with an ice pack and subjected to a constant voltage of 100V for one hour.  
2.2.3.5  Immunodetection 
After membrane transfer, the PVDF membrane was washed in PBS, rinsed in water, then 
dried between two filter papers overnight at 4°C. The membrane was then immersed in 100% 
methanol for 1 minute, rinsed in ultrapure water, and wet in 1X PBS for 1 minute. The 
membrane was then incubated in PBS-based Odyssey Blocking Buffer (Licor) on a shaker with 
gentle shaking at room temperature for one hour. The membrane was cut, and the part containing 
the rightmost 3 lanes (ladder, c-myc-tagged full-length MRPS2, and c-myc-tagged truncated 
MRPS2) was immersed in a solution of Odyssey Blocking Buffer containing 1:500 diluted c-
myc antibody raised in Goat and Tween-20 at a final concentration of .2%. The remainder of the 
membrane was immersed in a solution of Odyssey Blocking Buffer containing anti-MRPS2 
antibody raised in mouse at a dilution of 1:500 and Tween-20 at a final concentration of .2%. 
The primary antibody incubation was performed overnight at 4°C on a shaker with gentle 
shaking. Following primary antibody incubation, the membrane was washed 4 times for 5 
minutes each with 1x PBS with tween 20 at a final concentration of 0.1% (PBS-T) on a shaker 
 21 
with vigorous shaking at room temperature.  The membranes were then incubated in a solution of 
Odyssey Blocking buffer with Tween-20 at a final concentration of .2 and SDS at a final 
concentration of 0.01%, as well as secondary antibodies at a dilution of 1:20,000 (IRDy 800CW 
goat anti-mouse IgG1 from Licor for MRPS2, and IRDye 680LT conjugated donkey anti-goat 
IgG from Licor for c-Myc) for 1 hour at room temperature with gentle shaking. Following 
another wash step identical to that described above, the blot was rinsed in 1xPBS, then placed 
between two kimwipes to dry. 
2.2.4  Immunostaining 
Wildtype cells, cells from the E4 mutant cell line, and cells from both E3 mutant cell 
lines were seeded on glass coverslips at a concentration of 1x105/cm2 and allowed to grow for 5 
days. The cells were washed 3 times with cold PBS, fixed in 4% paraformaldehyde in PBS with 
gentle shaking at 4°C for 20 minutes, then washed 3 times with .3M glycine in PBS for 15 
minutes each time on a shaker at room temperature. The cells were then blocked for an hour at 
room temperature in a solution of PBS with .3M glycine, 1% donkey serum, and 3% bovine 
serum albumin.  Following another 5 15-minute PBS washing steps at room temperature, the 
cells were treated with a solution of 3% bovine serum albumin in PBS supplemented with 
tropoelastin antibody diluted 1:100 and fibrillin antibody diluted1:400. Following another 5 15 
minute PBS washing steps at room temperature, the cells were treated with a solution of solution 
of PBS with .3M glycine, 1% donkey serum, and 3% bovine serum albumin supplemented with 
secondary fluorescent antibodies and incubated in the dark at room temperature for 1 hour. 
Following another 3 15 minutes PBS washing steps at room temperature, the cells were 
incubated in a solution of PBS with 4',6-diamidino-2-phenylindole (DAPI) in a 1:1000 dilution 
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on a shaker in the dark at room temperature for 20 minutes. The coverslips were then subjected 
to a final washing stage, with 5 5-minute washes with PBS supplemented with .1% Triton-X-
100. The coverslips were then rinsed with water, carefully removed from the plates with a 
spatula, and left to dry cell-side-up for 30 minutes in the dark. 10 µl of Cytoseal™ 60 was 
dropped onto the center of glass microscope slides and the coverslips were then pressed cell-
side-down onto the slides, which were then left to dry in the dark. 
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3.0  RESULTS 
3.1 IDENTIFICATION AND CHARACTERIZATION OF MUTANT CELL LINES 
Sanger sequencing of PCR products of 42 cloned cell lines revealed three cell lines with 
apparent mutations in the targeted regions of Mrps2. To better resolve the mutations in these cell 
lines, PCR amplified target regions were subjected to plasmid cloning. Sanger sequencing of 
plasmid clones of the three mutant cell lines identified one cell line with a deletion mutation in a 
single allele of Mrps2, in exon 4, and two cell lines, each with unique deletion and insertion 
mutations in both alleles of exon 3. The WT/mutant heterozygote cell line -designated simply 
'E4'- contained a 34bp deletion on one copy of the Mrps2 gene, while the other copy of the 
Mrps2 contained no detectable changes from wildtype. One mutant/mutant compound 
heterozygote cell line -designated '11'- contained a 51 bp insertion and 1bp deletion in exon 3 of 
one copy of the Mrps2 gene and a 154-bp deletion in exon 3 of the other copy.  [(c.123_124ins51 
; c.180delC (p. P60Pfs*16),  g.2060_2105del (p.D34Ffs*70)]. The other mutant/mutant 
compound heterozygote –designated ‘10’- contains a 66bp deletion in exon 3 of one copy of the 
MRPS2 gene and a 39bp insertion in exon 3 of the other copy (g.2039_2213del;  
c.123_124ins39). 
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Figure 4. A schematic representation of the insertion mutation in clone 11.  
DNA from clonal cell lines and wildtype cells was extracted and the target region amplified using PCR. 
PCR products were cloned into E. coli to examine individual alleles of Mrps2 via Sanger sequencing. 
Exons (green), introns (red), and inserted region(blue) are drawn to scale. Sequence traces from selected 
regions of wildtype (WT) and biallelic clone 11 mutant cells (Clone 11 ins) have been aligned to highlight 
homology and differences. 
 
 
Figure 5. schematic representation of the deletion mutation in clone 11.  
DNA from clonal cell lines and wildtype cells was extracted and the target region amplified using PCR. 
PCR Products were cloned into E. coli to examine individual alleles of Mrps2 via Sanger sequencing. 
Exons (green) and introns (red) are drawn  to scale. Sequence traces from selected regions of wildtype 
(WT) and biallelic clone 11 mutant cells (Clone 11 del) have been aligned to highlight homology and 
differences. 
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Figure 6. A schematic representation of two types of mRNA variants observed in clones 10 
and 11.  
From top: Wildtype mRNA size, Exon 3 skip mRNA product, insertion/deletion mRNA product. 
 
 
The predicted consequences of the mutations are varied. In the case of E4, the deletion 
results in a premature termination at the 17th amino acid position of exon 5 (under normal 
conditions, MRPS2 is predicted to terminate at amino acid position 195 of Exon 5, which is 
where the first stop codon is in the wildtype reading frame). However, it is unknown whether the 
bulk of exon 5 actually serves a biological function or whether it is proteolytically removed 
during processing. 
In cell line 10, the 66bp deletion in exon 3 results in the deletion of the last 64 bases of 
exon 3, causing a frameshift that leads to the predicted premature termination of translation at 
amino acid position 7 of exon 4. The 39bp insertion on the other allele of exon 3 is not predicted 
to result in a premature termination of protein synthesis. 
In the case of mutant cell line 11, the combination of the 51bp insertion and the single 
base deletion results in a frameshift that results in a premature termination at the 16 amino acids 
residues downstream of the deletion, in the 16th amino acid of exon 4. On the other allele, the 
154-bp deletion results in the deletion of the last 44 bases of exon 3, resulting in a frameshift that 
results in a premature stop 70 amino acids downstream of the deletion.  
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3.1.1 Consequences of Mrps2 mutations at the mRNA level 
Raw Ct (threshold cycle) values were converted to expression-fold change values using a 
classic 2-ΔΔCT method with pairwise comparisons (see supplemental calculations)  (Schmittgen 
and Livak, 2008). The analysis identified no statistically significant reduction in Mrps2 mRNA 
levels for either the E4 cell line or a cell line that was subjected to the same treatment as the 
mutant cells but found to contain no mutations. There was, however, a 39.3% reduction in Mrps2 
levels for exon 3 mutant 10 (SD: 3.66%), and a 43.1% reduction in Mrps2 levels for Exon3 
mutant 11 (SD: 13.78%) (see graph 1).  
 
Figure 7. Expressionfold changes in MRPS2 mRNA 
 Significance bars represent 95% confidence intervals. 
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Table 7. Mrps2 cDNA clone sequencing results 
E3 Clone 10 
c.43_160del [total skipping of Exon 3] 11 
c.43_160delins87 2 
c.129_130instGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCA
A 
1 
Total 14 
E3 Clone 11 
c.116_160delinsCAGAACCCCTGTGGCCTG 7 
c. 43_160del [total skipping of Exon 3] 1 
Wildtype 1 
Total 8 
  
In analyzing sequence data for the two biallelic mutant clones (Table 6), we confirmed 
the existence of PCR products corresponding to mRNA transcripts with complete knockout of 
Exon 3 in both the Clone 10 and Clone 11 samples, as well as insertion and deletion products 
unique to Clone 10 and Clone 11. The clone 10 found to produce three types of Mrps2 
transcripts: 11 cDNA clones showed a complete skipping of exon 3, in 2 cDNA products exon 3 
was replaced by an 87 bp fragment corresponding to the final 87 bases of intron 3, and 1 cDNA 
clone with the insertion of a 36 bp sequence in the guide region. After removing 4 unreadable 
sequences, the Mrps2 transcript produced by Clone 11 were represented by a total of 8 cDNA 
clones: 1 with a complete skipping of exon 3, 1 corresponding to the wildtype sequence, and 7 
with a deletion of the final 48 bases of exon 3 and insertion of 17 bases from intron 3, 
corresponding to the 17 bases directly 3’ of the Clone 11 deletion.  
The reasons the exon skip products are more abundant in the clone 10 population, while 
the insertion/deletion products are more abundant in the clone 11 population, likely involve the 
sequences of the insertions and the extent of deletions, and how they could affect recognition of 
splice sites by the spliceosome. In the case of clone 10, it could be that both the insertion and the 
deletion may induce exon skipping. Of note, the motif CAGattt appears at both the canonical 
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exon 3 – exon 4 splice junction and the new intron 3 - exon 4 splice junction. Using the Splice 
Site Prediction tool from the Berkely Drosophila Project, we verified that the new splice acceptor 
site is predicted to have comparable activity to the canonical intron 3 – exon 4 splice acceptor 
site (new acceptor site score: .98, canonical acceptor site score: .97) 
 In the case of clone 11, it seems that the mRNA product containing a partial deletion of 
exon 3 and insertion of part of intron 3 is the more abundant product, while transcripts with total 
skipping of exon 3 are comparably rare. It may also be possible that the reason mRNAs 
representing the insert mutation are not well-represented is that the transcripts are degraded via 
nonsense-mediated decay.  
In the case of the insertion of 87 bases from intron 3 in the clone 10, the mutation is 
predicted to result in a premature stop 10 amino acid residues after the start of the insertion 
(p.Gly15Aspfs*11). The other insertions and deletions result in no predicted frameshift or 
premature termination. 
 
Figure 8. PCR amplification of cDNA.  
Amplified region spans start codon through 465th base of coding region (121st base of 
Exon 4).  
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3.1.2 Western Blot 
The Western blot obtained from the secreted protein fraction of cultured cells reveals a 
secreted protein around 8 kilodaltons in size that reacts with the anti-MRPS2 antibody. The cells 
transfected with the c-myc tagged MRPS2 display a band in the same size range when exposed 
to anti-c-myc antibody. There also appears to be a protein product around 90kD in mass that 
reacts with the c-myc antibody.  
The intracellular protein sample containing protein extracts from the biallelic mutants did 
not yield a readable blot, but previous runs showed a protein band in the 15kDa range (Figure 9) 
 
Figure 9. Immunoblotting for MRPS2 in mutant and overexpressing cell lines. 
Lysate and concentrated conditioned media were collected from wildtype (WT), MRPS2 
heterozygote mutant (E4), and cells stably transfected to express c-Myc-tagged full-length 
(MRPS2 F) or truncated (MRPS2 T) MRPS2. First and last lanes contain molecular weight 
standards. Numbers indicate molecular weight in kilodaltons. 
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Figure 10. Immunoblotting for MRPS2 and c-Myc in mutant and overexpressing cell lines. 
Conditioned media was collected from wildtype (WT), MRPS2 heterozygote mutant (E4), 
biallelic mutant (10, 11), and cells stably transfected to express c-Myc-tagged full-length 
(MRPS2 F) or truncated (MRPS2 T) MRPS2. First lane and cut lane contain molecular weight 
standards. Lanes 2-7 were probed using an MRPS2 andtibody, whereas lanes 9 and 10 were 
probed for c-Myc. Numbers at the left side of the image indicate molecular weight in kilodaltons. 
3.1.3 Immunostaining 
Though the cells were all seeded at equal concentration, by the end of the 5-day waiting 
period, the cells on the WT and E4 coverslips were visibly more confluent than the cells on the 
cell line 10 and cell line 11 coverslips. There also appears to be a difference in tropoelastin 
morphology (Figure 11). The WT and E4 cell lines appear similar to each other in that the elastin 
is more fibrous, while in both biallelic mutant cell lines, the tropoelastin appears to be deposited 
in more evenly distributed sheets. Another notable difference is the presence of enlarged nuclei 
in cell line 10. Fibrillin morphology could not be analyzed because the primary antibody appears 
to have failed to demonstrate ECM specificity.  
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Figure 11. Fluorescent staining of biallelic mutant and wildtype cells.  
Cells were seeded at a density of 300,000 cells/well and allowed to grow for 5 days before being 
fixed in paraformaldehyde and treated with tropoelastin antibody (green), and DAPI (blue). (A) 
Comparison of Wildtype (WT) and biallelic mutant 10 (10) nuclei. (B) Comparison of Wildtype 
(WT) and biallelic mutant 11 (11) tropoelastin. (C) Example of peeling in biallelic mutant 10, 
DAPI and tropoelastin overlay.  
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4.0  DISCUSSION 
The experiment was successful in generating biallelic mutations in Mrps2, though the 
small quantity of mutants relative to the size of the clonal population leaves considerable room 
for improvement. The drawn-out process we had to employ to tailor the protocol to the difficult-
to-transfect RFL6 cells –which was only briefly touched upon in this document - has reaffirmed 
the common wisdom that getting optimal results often requires considerable deviation from the 
protocols supplied by journals and manufacturers.  
The proportions of cDNA sequencing products with either partial or complete deletions 
of exon 3 correspond to the relative intensity of bands observed when the PCR products are run 
on a gel. The difference in sizes of the bands also correspond with the difference between the 
sizes of the complete and partial deletions of exon 3. 
The fact that a deletion that encompasses the exon-intron junction results in complete 
exon skipping is unsurprising, as the sequences of the exon-intron junctions are important for 
proper splicing of exons. Similar cases have been consistently documented in the literature. The 
fact that the exon skipping occurred predominantly in mutant 10 and was only observed in one 
clone isolated from mutant 11 is consistent with the fact that the deletion in clone 11 just barely 
reaches into intron 3, deleting only two nucleotides in the 5’ end of the intron, while the deletion 
in clone 10 deletes the first 110 base pairs in the 5’ end of intron 3.  
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What is surprising is that only sequences deletion of parts of exon 3 were detected in the 
PCR products obtained from amplifying cDNAs from mRNAs obtained from the two biallelic 
mutant cell lines. One might have expected to find sequences larger than wildtype transcripts 
corresponding to the insertions found in either cell line, but these do not appear to be represented 
in the sequences obtained from the clones.  
The fact that tropoelastin deposition appears to be affected in the cell lines with biallelic 
mutations of Mrps2 is consistent with what was observed in the families of the two patients, but 
the data collected so far does little to elucidate precisely what the mechanism may be. The fact 
that the DAPI stain seems to show that the biallelic mutant cells possess enlarged nuclei is also 
useful. Swelling of the nuclei has been found to be associated with mitochondrial disease in 
mouse models, and there is evidence that this phenotype is correlated with oxidative stress 
(Wallace and Fan, 2009). Oxidative stress has been observed to result from disruption of electron 
transport chain function, so disruption of the formation of the mitoribosome, which is 
responsible for ETC assembly, leading to oxidative stress, is a likely culprit in the development 
of the phenotype observed in the patients (Jones, 2006). 
While this explanation partially satisfies the question of how a direct link between 
molecular genetics could lead to the observed cellular phenotype, it fails to fully explain why 
fibroblasts and elastic fiber assembly in particular are affected, as wrinkly skin is not a universal 
manifestation. Given that the mitoribosome has evolved to specialize in the synthesis of ETC 
proteins, it is possible that disruption of different specific elements of the ribosome could lead to 
disruption of different specific ETC elements, leading to different phenotypes, but beyond that, 
not much more can be concluded from the results of this experiment and the available literature, 
and further analysis is needed. Perhaps the relationship is more simple, and the key is simply the 
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balance between the degree to which ROS species upregulation and ATP downregulation are 
affected. The accumulation of reactive oxygen species has been connected to the disturbance of 
the activity metalloproteases responsible for degrading fibrillin, which offers another possible 
mechanism for the manifestation of a wrinkly skin phenotype (Klein and Bischoff, 2011).  
The Western blot is potentially very informative. The fact that the c-myc antibody reacted 
with the same protein product that reacted with the Mrps2 antibody in the cells transfected with 
the c-myc-tagged Mrps2 transcript indicates that the protein that the Mrps2 antibody is reacting 
with in the other samples is indeed a fragment of Mrps2. As the c-myc tag was affixed to the C-
terminus of the Mrps2, we can infer that the fragments are C-terminal fragments of Mrps2 that 
are proteolytically cleaved during processing. The lowered intensity of the Mrps2 signal in the 
mutant cell lines compared to the wildtype cell line is consistent with the lowered mRNA 
abundance due to nonsense-mediated decay and/or failure of the antibody to bind as effectively 
to Mrps2 due to altered amino acid sequence caused by frameshifts and deletions of large 
portions of the protein. It should be noted that a the middle of a region that is highly conserved 
between the Rat and Human versions of the protein lies roughly 70 amino acid residues (~8 
kilodaltons), upstream of the C terminus. The fact that the fragment is found in the extracellular 
space may be related to the fact that the extracellular matrix morphology is altered, but 
determining a mechanism for such an effect  
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5.0  CONCLUSIONS 
Taken together, these data present a tantalizing picture of MRPS2’s function in the cell. 
Further investigation is needed to determine the significance of our findings. Of highest priority 
is the analysis of indicators of mitochondrial function and characterization of ECM dysfunction. 
The observation that growth seems to be impaired in the biallelic mutant cells merits 
some follow-up. During the preparation of slides, the mutant 10 and 11 cells were more 
susceptible to sloughing off from the coverslips than the WT or E4 cells, despite being less 
confluent. All else being equal, sloughing will occur more readily in overconfluent cells rather 
than underconfluent cells, so this paradoxical observation suggests that the biallelic mutant cells 
are not merely growing slowly, but also failing to adhere properly for some reason. A cell 
adhesion assay will shed light on the severity of this dysfunction. One of the more pressing 
questions is precisely how the disruption of mitoribosomal formation could be causing disruption 
of the mutant cells. Untangling the complex network of cause and effect that could be at play 
here will require controlled study of several variables associated with fibroblast health. An ATP 
assay on cell lysate could determine whether mitochondrial energy production is being altered. 
Oxygen and pH flux experiments using a Seahorse instrument could be used to quantify 
oxidative phosphorylation and glycolysis; this could help clarify how the production of ATP is 
being disrupted, and whether disruption of ETC formation could be causing some sort of 
diversion of the normal cellular respiration pathway. Retrying the fibrillin stain and staining for 
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other ECM components such as fibronectin could provide further information on how ECM 
morphology is affected. In the long term, if the knockdown process were to be repeated to 
produce more mutants with more severe Mrps2 mutations (perhaps generating another mutation 
in the existing mutants), it could be productive to use a more recent version of the Px459 
plasmid, as the original version that was used in the experiment was later found to possess a less 
efficient version of the puromycin resistance gene. This flaw was rectified in the more recent 
version of the plasmid, pSpCas9 (BB)-2A-Puro (PX459) V2.0. Finally, a more thorough 
characterization of the secreted Mrps2 fragment would be valuable, and this could be obtained 
by immunoprecipitation. 
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